论文部分内容阅读
目的观察单唾液四己糖神经节苷脂(Monosialoganglioside,GM1)联合巴曲酶注射液治疗急性脑梗死的临床疗效。方法急性脑梗死患者120例,随机分为巴曲酶组、神经节苷脂GM1组、联合组,14d为1个疗程。观察临床疗效、神经功能缺损评分(NFDS)、血浆纤维蛋白原(Fb)的改变。结果联合组有效率92.5%,高于巴曲酶组(72.5%)(P<0.05),明显优于GM1组(57.5%)(P<0.01)。3组治疗后NFDS较治疗前均有改善(P<0.05或P<0.01);联合组治疗后NFDS改善优于巴曲酶组与GM1组(P<0.05)。巴曲酶组与联合组Fb含量均明显降低,与治疗前比较有统计学意义(P<0.01);联合组较GM1组Fb降低明显(P<0.05)。结论单唾液四己糖神经节苷脂、巴曲酶联合应用治疗急性脑梗死,可达到协同互补的治疗效果,优于单用单唾液四己糖神经节苷脂或巴曲酶的治疗效果。
Objective To observe the clinical efficacy of monosialoganglioside (GM1) combined with batroxobin in the treatment of acute cerebral infarction. Methods 120 patients with acute cerebral infarction were randomly divided into batroxobin group, ganglioside GM1 group, combined group, 14d for a course of treatment. To observe the clinical efficacy, neurological deficit score (NFDS), plasma fibrinogen (Fb) changes. Results The effective rate of combined group was 92.5%, higher than that of batroxobin group (72.5%) (P <0.05), which was significantly better than that of GM1 group (57.5%) (P <0.01). NFDS in all three groups was improved after treatment (P <0.05 or P <0.01). The NFDS improvement in combination group was better than that in Batroxobin group and GM1 group (P <0.05). The Fb content of batroxobin group and the combination group were significantly lower than that of the control group (P <0.01). The Fb level of the combined group was significantly lower than that of the GM1 group (P <0.05). Conclusion Single saliva tetrahexose ganglioside and batroxobin combined treatment of acute cerebral infarction, synergistic complementary therapy can be achieved, better than single saliva tetrahexose ganglioside or batroxobin treatment effect.